 VOLASERTIB IN COMBINATION WITH LOW-DOSE CYTARABINE IN PATIENTS AGED 65 YEARS AND ABOVE WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKAEMIA, WHO ARE INELIGIBLE FOR INTENSIVE REMISSION INDUCTION THERAPY POLO-AML-2: 